S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

Avivagen Stock Forecast, Price & News

-0.02 (-4.88 %)
(As of 09/24/2021 12:09 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume2,971 shs
Average Volume91,131 shs
Market CapitalizationC$22.21 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VIV News and Ratings via Email

Sign-up to receive the latest news and ratings for Avivagen and its competitors with MarketBeat's FREE daily newsletter.

About Avivagen

Avivagen Inc., a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers products based on its OxC-Beta technology, such as OxC-beta Livestock, a premix for livestock feeds; and Vivamune Health Chews supplements for companion animals. It has operations in Mexico and Latin America. The company was formerly known as Chemaphor, Inc. and changed its name to Avivagen Inc.in May 2012. Avivagen Inc. was founded in 2005 and is headquartered in Ottawa, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.88 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Avivagen (CVE:VIV) Frequently Asked Questions

What stocks does MarketBeat like better than Avivagen?

Wall Street analysts have given Avivagen a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Avivagen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Avivagen's next earnings date?

Avivagen is scheduled to release its next quarterly earnings announcement on Wednesday, September 29th 2021.
View our earnings forecast for Avivagen

How has Avivagen's stock been impacted by COVID-19 (Coronavirus)?

Avivagen's stock was trading at C$0.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VIV shares have decreased by 35.0% and is now trading at C$0.39.
View which stocks have been most impacted by COVID-19

Who are Avivagen's key executives?

Avivagen's management team includes the following people:
  • Mr. G. F. Kym Anthony, CEO, Pres & Director (Age 65, Pay $362.43k)
  • Dr. Graham Burton, Co-Founder, Chief Scientific Officer & Director
  • Mr. Christopher Boland, Chief Financial Officer
  • Mr. Drew Basek, Director of Investor Relations
  • Ms. Tracy Gillett BVSC, Marketing Mang.

What other stocks do shareholders of Avivagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avivagen investors own include (ATE), Astrotech (ASTC), Arcturus Therapeutics (ARCT), (AQB), Aptose Biosciences (APTO), Appili Therapeutics (APLIF), Argan (AGX), Applied Genetic Technologies (AGTC), The AES (AES) and AbbVie (ABBV).

What is Avivagen's stock symbol?

Avivagen trades on the Canadian Venture Exchange (CVE) under the ticker symbol "VIV."

How do I buy shares of Avivagen?

Shares of VIV and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Avivagen's stock price today?

One share of VIV stock can currently be purchased for approximately C$0.39.

How much money does Avivagen make?

Avivagen has a market capitalization of C$22.21 million and generates C$1.32 million in revenue each year.

How many employees does Avivagen have?

Avivagen employs 14 workers across the globe.

What is Avivagen's official website?

The official website for Avivagen is www.avivagen.com.

Where are Avivagen's headquarters?

How can I contact Avivagen?

Avivagen's mailing address is Av Engenheiro Luis Carlos Berrini, 1376 32 andar, Sao Paulo, Sao Paulo 04.571-936. The company can be reached via phone at 613-949-8164.

This page was last updated on 9/26/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.